Recent studies have identified TRPC5, which is also expressed in kidney, as a promising therapeutic target for protecting against focal segmental glomerulosclerosis (FSGS) through selective inhibition.[24] Sadler et al. Here, TRPC5 is linked to focal segmental glomerulosclerosis.